Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics

The phytochemical resveratrol has undergone extensive preclinical investigation for its putative cancer chemopreventive properties. Low systemic availability of the parent compound due to rapid and extensive metabolism, may confound its usefulness as a potential agent to prevent malignancies in orga...

Full description

Saved in:

Bibliographic Details
Main Authors:	Howells, L. M., Berry, D. P., Elliott, P.J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., Gescher, A. J.
Format:	Artigo
Language:	Inglês
Published:	2011
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3173869/ https://ncbi.nlm.nih.gov/pubmed/21680702 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-11-0148
Tags:	Add Tag No Tags, Be the first to tag this record!

Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics

Similar Items